Absorbable device implanted as part of clinical trial
WellSpan Health | 06.28.13
Absorb is a small mesh tube designed to open a blocked heart vessel, restore blood flow to the heart and then dissolve into the blood vessel over time.
Cardiologists at WellSpan York Hospital recently implanted a small mesh tube that is designed to open a blocked heart vessel, restore blood flow to the heart and then dissolve into the blood vessel over time.
WellSpan Heart & Vascular is using the device, known as Absorb, as part of a national clinical trial.
ABSORB III is the first U.S. clinical trial to evaluate the potential benefits of Absorb in comparison to a medicated metallic heart stent, also called a drug eluting stent, in patients with coronary heart disease.
“We are excited to have been the first in the region to implant the Absorb device,” said William Nicholson, MD, an interventional cardiologist with Cardiac Diagnostic Associates, PC.
“While WellSpan Heart & Vascular often uses cutting-edge technology, we don’t always get to be the first in the region to perform a procedure.”
Dr. Nicholson said participating in the clinical trial helps validate the strong program that has been built at WellSpan Heart & Vascular.
“It acknowledges the expertise available at WellSpan York Hospital for surgical, interventional and imaging-related cardiac care.”
Unlike a metallic stent that remains permanently in the body, Absorb is referred to as a scaffold to indicate that it is a temporary structure. The device, manufactured by Abbott, is made of naturally absorbable material that is commonly used in medical implants such as dissolvable sutures.
The ABSORB III clinical trial will enroll approximately 2,250 patients, the majority in the United States.
Heart disease is a leading cause of death for both men and women in the United States, accounting for one in every six deaths.